<DOC>
	<DOCNO>NCT02713932</DOCNO>
	<brief_summary>The Italian Society Invasive Cardiology Registry Percutaneous Aortic Valve prospective Italian registry include several center perform TAVI , collect baseline , procedural outcome data .</brief_summary>
	<brief_title>The Italian Society Invasive Cardiology Registry Percutaneous Aortic Valve</brief_title>
	<detailed_description>Aortic valve stenosis common degenerative valve disease elderly , prevalence 1-2 % age group &gt; 65 year 4 % patient age &gt; 85 . The natural history characterize poor prognosis survival rate 62 % 1 year , 32 % 5 year 18 % 10 year symptom onset . Predictors death age &gt; 75 year , poor leave ventricular ejection fraction , congestive heart failure , chronic obstructive pulmonary disease , severe mitral regurgitation pulmonary hypertension . The gold standard therapy , improve survival , severe aortic stenosis surgical aortic valve replacement mechanical biological prosthesis . Cardiac surgery therapy choice patient severe aortic valve stenosis leave ventricular dysfunction symptomatic lipothymia syncope , angina pectoris , heart failure . Criteria high surgical risk : leave ventricular failure , coronary artery disease , previous cardiac surgery coronary artery bypass , chronic obstructive pulmonary disease , and/or advanced age comorbidity , contraindication intervention . Frequently cardiac surgery perform elderly patient high surgery risk . In Euro Heart Survey 33 % patient single valve disease , New York Heart Association class III IV , operate concomitant disease reduce life expectancy . The need provide therapeutic option patient consider high surgery risk , stimulate development prosthetic valve implantable percutaneous transcatheter technique . The percutaneous treatment valvular aortic stenosis potential advantage term reduction hospitalization elderly patient high risk peri-operative mortality morbidity , well avoid treatment oral anticoagulant . The experience positive , immediate favorable result term hemodynamic clinical improvement . Since procedure initial stage clinical application , become necessary uniform standardize data collection ass effectiveness procedure , incidence acute late complication , performance biological valve prosthesis . The investigator propose establishment observational registry percutaneous aortic valve replacement perform Italian Interventional Cardiology Laboratory . The objective : - Record clinical criterion use ass indication percutaneous aortic valve replacement different center - Record anatomical morphological criterion vascular access thoraco abdominal aorta , evaluate noninvasive invasive diagnostic test ( echocardiography , multislice angiographic compute tomography , aortography ) particular calcification tortuosity aorto-iliac-femoral axis , degree calcification aortic valve thoracic aortic wall calcification . - Record type device use percutaneous aortic valve replacement - Observe different way procedure ( type access , anesthetic protocol , procedural delay , aortic valvuloplasty , forth ) - Follow procedure-related complication / prosthesis implantation . - Acute complication : - Cerebral ischemia - Arrhythmias - Pericardial effusion / cardiac tamponade - Aortic valve insufficiency - Periprosthesis insufficiency - Myocardial ischemia - Kidney diseases - Conversion cardiac surgery - Complications related arterial vascular access - Late complication - Residual aortic valve insufficiency - Arrhythmias need pacemaker - Coronary Ischemia - Kidney diseases - Endocarditis - Post Procedure hospital stay - Evaluate result 30 day , 6 , 12 , 18 24 month follow : - echocardiographic mean transvalvular aortic gradient - valvular and/or periprosthesis insufficiency - leave ventricular ejection fraction - Evaluate clinical outcome 30 day , 6 , 12 , 18 24 month follow - New York Heart Association functional class - Medical therapy heart failure - Number hospitalization heart failure Information obtain analyzed used standardize make appropriate indication percutaneous aortic valve replacement improve standardize protocol procedure , assess immediate long-term effectiveness technique , monitor acute late complication relate especially verify performance tissue valve medium long term . The hemodynamics center wish join register send complete form steer committee . Once registered receive identification code pas word record data . Registration patient underwent percutaneous aortic valve replacement prosthetic heart valve CE mark , consecutively enrolled period 24 month . Use paper electronic case report form , divide 4 part : I . Personal detail , medical history , clinical assessment / Instrumental II . procedure III . Post-procedure hospital stay ( 24 hour , 48 hour , discharge ) IV . Follow 30 day , 6 month , 12 month , 18 month , 24 month The data compile analyzed quarterly basis discuss participate center semi-annual meeting Primary end-points : 1 . Feasibility procedure ( functioning device , procedural success ) 2 . Access stenotic native aortic valve 3 . Effectiveness position valve 4 . Removal transport system 5 . Procedural success determine efficacy valve system reduction gradient , hemodynamically significant valvular regurgitation , assess angiography color Doppler echocardiography 6 . Major intraprocedural adverse event 30 day , 3 , 6 , 12 , 18 24 month 1 . Major arrhythmias 2 . Myocardial infarction , 3 . Cardiac tamponade 4 . Malfunctioning valve 5 . Emergency surgical aortic valve replacement 6 . Emergency aorto-coronary bypass percutaneous coronary angioplasty 7 . Cardiogenic shock 8 . Infective endocarditis 9 . Stroke transient ischemic attack 10 . Aortic dissection 11 . Dissection peripheral vessel 12 . Vascular perforation 13 . Acute occlusion artery access 14 . Major bleed 15 . Death 7 . New York Heart Association functional class 30 day , 6 , 12 , 18 24 month 8 . Left ventricle ejection fraction measure echocardiography 30 day , 6 , 12 , 18 24 month 9 . Valve functioning : valve area , residual mean gradient , aortic regurgitation assess color Doppler echocardiography 30 day , 6 , 12 , 18 24 month 10 . Incidence paravalvular regurgitation 30 day , 6 , 12 , 18 24 month 11 . Incidence infective endocarditis 30 day , 6 , 12 , 18 24 month 12 . Incidence vascular complication need surgery</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Aortic Valve Insufficiency</mesh_term>
	<criteria>Patients transcatheter aortic valve implantation attempt participate center . None except failure obtain informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Aortic valve stenosis</keyword>
	<keyword>Aortic valve regurgitation</keyword>
	<keyword>Transcatheter aortic valve implantation</keyword>
</DOC>